Clinical trial MCL-R2 Elderly
Efficacy of alternating immunochemotherapy consisting of R-CHOP + R-HAD versus R-CHOP alone, followed by maintenance therapy consisting of additional lenalidomide with rituximab versus rituximab alone for older patients with mantle cell lymphoma
| Cancers | |
|---|---|
| Organ | Non-Hodgkin lymphoma |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Lysarc |
| EudraCT Identifier | 2012-002542-20 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT01865110 |
| Inclusion criteria | 1st line/ >= 60 years old and ineligible for autologous transplant/ Ann Arbor stage II-IV |
| Last update |